4th Annual Stem Cell Summit - New York, February 17, 2009 4th Annual Stem Cell Summit - Online Pre-Registration Available Now

Agenda - 2009 Stem Cell Summit

Tuesday, February 17, 2009 8:00 am - 7:00 pm (Eastern Time)

Preliminary Agenda
Please visit this page for presentation schedule updates. If you are interested in more information or conference sponsorship, please contact us.

7:00 - 8:00

Registration & Continental Breakfast

Welcome & Introductions to the Stem Cell Summit

8:00 - 8:15
Overall Welcome &Introduction to the 4th Annual Stem Cell Summit - The Outlook for Commercialization in Stem Cells 2009-2019
Robin R. Young, CFA
President and Publisher
RRY Publications &
PearlDiver Data, Inc.
8:15 - 8:35
Cell Therapy: MSCs as Regulated Drugstores
Arnold Caplan, PhD
Professor of Biology and General Medicine Sciences (Oncology) Case Western Reserve University

8:35 - 4:15


Company Presentations

Embryonic Stem Cells

   
8:35 - 8:45
Novocell, Inc.
Mitch Fisher,
Senior Vice President

Novocell, Inc. is a stem cell engineering company dedicated to creating, delivering and commercializing cell and drug therapies to treat diabetes and other chronic diseases.
8:47 - 8:57
Geron Corp.
Jane S. Lebkowski, PhD,
Sr. Vice President
Geron Corporation develops and commercializes cell-based therapies derived from its human embryonic stem cell platform for applications in various diseases.
8:59 - 9:09
California Stem Cell, Inc.
Hans S. Keirstead, PhD, Chairman, Scientific Advisory Board
California Stem Cell is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations.
9:11 - 9:21
Stemina, Inc.
Gabriela Cezar, DVM, PhD,
Chief Scientific Officer

Stemina’s innovative cell based assays arise from the strategic convergence of two groundbreaking technologies: stem cells and metabolomics
9:23 - 9:33
Histogen, Inc.
Gail K. Naughton, Ph.D, CEO
Histogen, Inc. is a regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor that mimics the embryonic environment.
9:35 - 9:45
Aruna Biomedical, Inc.
Steven Stice, PhD,
Chairman and Chief  Scientific Officer

Aruna Biomedical is a pioneer and leader in providing innovative products and services derived from human stem cells.


Adult Stem Cells

9:47 - 9:57
Aldagen, Inc.
Ed Field,
President & COO
Aldagen is a regenerative medicine company developing and commercializing products to treat vascular and degenerative diseases.
9:59 - 10:09
Genzyme
Stephen Potter Senior Vice President , Corporate Development
Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company’s products and services are focused on rare inherited disorders, kidney disease, orthopaedics, transplant, cancer, and diagnostic testing.
10:11 - 10:23
Osiris
therapeutics
C. Randal Mills, PhD,
President, CEO, & Director
Chondrogen™ is currently being evaluated in a clinical trial for regeneration of the meniscus in the knee and prevention of osteoarthritis.
10:25 - 10:35
MaxCyte, Inc.
Madhusudan Peshwa, Ph.D,
Vice President,
Research & Development

Maxcyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies.
10:37 - 10:47
AllCells, LLC
Jay Tong, CEO

AllCells’ products include a wide variety of unprocessed and purified normal human blood and bone marrow cells.
10:49 - 10:59
Moraga Biotechnology Corporation
John F. Wong, PhD,
Chairman & CEO

Moraga Biotechnology Corporation is an adult stem cell-based company headquartered in Los Angeles, California.
11:01 - 11:11
Arteriocyte, Inc.
Donald J. Brown, CEO
Arteriocyte’s focus is stem cell-based therapies to treat ischemia in patients with coronary artery disease, peripheral vascular disease, stroke, and renal ischemia.
11:13 - 11:23
Aastrom Biosciences, Inc.
George W. Dunbar, CEO, President & Director
Aastrom Biosciences, Inc. is developing autologous cell products based on its proprietary Tissue Repair Cell (TRC) technology.
11:25 - 11:35
Gamida Cell Ltd.
Yael Margolin, PhD,
CEO
Gamida Cell Ltd. is a world leader in stem cell expansion technologies and therapeutic products.
11:37 - 11:47
Stematix
David C. Boner
Chairman & CEO
Stematix is a regenerative medicine technology and solutions provider positioned to accelerate safe and effective global use of stem cell therapies.
11:49 - 11:59
Garnet BioTherapeutics, Inc.
Gerri Henwood,
CEO
Garnet BioTherapeutics is developing the next generation of biomedicines by harnessing the therapeutic potential of the human cell.

12:00 - 1:00


Luncheon


1:00 - 1:30


Scientific Panel Presentations

Wise Young, MD, PhD,
Professor II

Richard H. Shindell Chair in Neuroscience.
Founding Director, W.M. Keck center for Collaborative Neuroscience
Rutgers, the State University of New Jersey
Bret A. Ferree, MD
Orthopedic Surgeon
Reconstructive Orthopaedics Inc.
Cincinnati, OH

Kevin Stone, MD
Orthopedic Surgeon
The Stone Clinic
San Francisco, California

 


1:30 - 1:45


Scientific Panel Question & Answer

 


Adult Stem Cells

1:45 - 1:55
NuVasive
Tyler Lipschultz,
VP, Biologics

NuVasive’s mission is to provide safe and reproducible procedural solutions with platform technology for the treatment of lumbar and cervical degenerative conditions.
1:57 - 2:07
TiGenix NV
Gil Beyen,
Managing Director & CEO
TiGenix is a venture-backed, private biotech company that was created as a spin-off from the universities of Leuven and Gent in Belgium.
2:09- 2:19
Cellerix
Living Medicines

Edwardo Bravo, MBA, CEO


Cellerix is leading the development of a new generation of treatments using expanded adult stem cells from adipose tissue (eASCs).
2:21- 2:31
StemCyte, Inc.

Kenneth J. Giacin, MBA, MS
Chairman & CEO


StemCyte, Inc. is a leading, global umbilical cord blood ("UCB") stem cell transplantation and therapeutic products company. StemCyte's products are currently being used to treat two to three patients per week worldwide who suffer from a variety of blood cancers and immune and genetic disorders.
2:33- 2:43
Athersys
William (B.J.) Lehmann, J.D.
President & CEO
Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics designed to treat significant and life-threatening diseases. The Company's lead programs are in the areas of obesity, cardiovascular disease (myocardial infarction), and bone marrow transplant support.
 

 

Tools & Instruments

2:45 - 2:55
Cytori
Therapeutics
Kai Pinkernell MD,
Sr. Director of Regenerative Cell Technology
Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue.
2:57 - 3:07
Cognate BioServices, Inc.

Alan K. Smith, PhD,
President & CEO


Cognate BioServices, Inc. provides full support to companies and institutions engaged in the development of cell-based products and therapies.
3:09 - 3:19
Harvest Technologies Corp.
Gary D. Tureski,
Co-Founder & President
Improving patient outcomes by enhancing the body's normal healing process using adult stem cells and growth factors.
3:21 - 3:31
Vet-Stem, Inc.
Robert J. Harman, DVM, MPVM
CEO & Founder

Vet-Stem’s regenerative medicine uses a concentrated form of autologous, adipose-derived adult stem cells to treat traumatic and degenerative diseases within the veterinary market.
3:33 - 3:43
BioE Corp.
Michael Haider,
President & CEO
BioE provides innovative Cell Biologics technologies for the biomedical industry.
3:45 - 3:55
Progenitor Cell Therapy, Inc.
Robert A. Preti, PhD,
President & Chief Scientific Officer
Progenitor Cell Therapy is a client-based cell therapy services company that supports the development of cellular therapies.
3:57 - 4:07

Histogenics, Inc.

F. Ken Andrews
President & CEO
Histogenics develops and manufactures products that improve the body's ability to regenerate healthy cartilage, improve joint function and prevent degenerative disease.
4:09 - 4:19
Tissue Genesis, Inc.
Stuart Williams, PhD,
Chief Science Officer
Tissue Genesis, Inc. is an emerging highgrowth
company in the field of regenerative medicine, using a patient’s own therapeutic cells to coat implants, repair damaged tissue, heal disease, and address other medical concerns.
4:21 - 4:31
Incel Corp. LLC
Mary Pat Moyer, PhD,
Founder, President, CEO & CSO
INCELL manufactures products for cell culture and research applications.

4:33 - 4:43

SpineSmith Partners LP

Richard Suzuki, PhD,
Director of Research & Development
SpineSmith designs, develops and markets implants and biologics for surgical fixation, correction and tissue regeneration of the spine. Their technology focuses on the stabilization and treatment of spinal and orthopedic disorders.

4:45 - 5:00


Robin R. Young, CFA
Closing Remarks


5:00 - 7:00

Reception and Networking

 

 

Stem Cell Summit Executive Summary - Stem Cell Analysis & Market Forecasts